ST
Seawolf Therapeutics
United States · Biotech · Healthtech
Seawolf Therapeutics develops DNA-based medicines using a redosable lipid nanoparticle delivery platform.
Product
Seawolf aims to treat metabolic and rare diseases by enabling patients’ cells to produce therapeutic proteins. Its TRIDENT platform packages DNA in lipid nanoparticles and helps it reach the cell nucleus. The company is developing preclinical programs designed to support repeat dosing.
Funding history
2 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A financing disclosure | Undisclosed | Alexandria Venture Investments — ParticipantCRISPR Therapeutics — ParticipantEli Lilly and Company — ParticipantMPM BioImpact — ParticipantNovartis Venture Fund — ParticipantPathway to Cures — ParticipantSixty Degree Capital — ParticipantVersant Ventures — Participant | |
| Seed financing disclosure | Undisclosed | Versant Ventures — Lead |